首页 Myovant Sciences Ltd.(usMYOV)-基本信息

Myovant Sciences Ltd.(usMYOV)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:17.92

最高价:19.05

成交量:493357.0

昨收价:17.86

最低价:17.7

最新价:18.949

行情图标
概要信息

英文名称:Myovant Sciences Ltd.


简介:Myovant Sciences Ltd.是根据百慕达法例注册成立于2016年2月2日


电话:44-203-189709


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Myovant Sciences是一家临床阶段的生物制药公司,专注于开发和商业化用于女性健康疾病和其他内分泌相关疾病的创新疗法。公司的主导候选产品是relugolix,一种口服,每日一次,小分子,作为促性腺激素释放激素(GnRH),受体拮抗剂。Myovant Sciences正在推进Relugolix治疗与子宫肌瘤,子宫内膜异位症相关的疼痛和晚期前列腺癌相关的重的月经出血。迄今为止,Relugolix在超过1,300名受试者中进行了评估,在I期和多个大型随机临床II期临床试验中,其中一些正在进行。这些试验在每种适应症中产生有利的结果。在这些试验中,显示relugolix通常具有良好的耐受性,并且成功地抑制女性中的雌激素和孕酮水平以及男性中的睾酮水平。女性对雌激素和孕酮水平的抑制已经显示有效地治疗子宫肌瘤和子宫内膜异位的症状,并且男性中睾酮水平的抑制已经显示有效地治疗晚期前列腺癌。在216名女性的双盲、安慰剂对照的2期临床试验中,relugolix显着降低了与子宫肌瘤相关的月经失血。结果对于每个治疗组与安慰剂具有统计学显着性,在每天40mg(p <0.0001)剂量录得最大治疗效果。在一项双盲,安慰剂对照的II期临床试验中,487名患有子宫内膜异位症的妇女,relugolix减少了与子宫内膜异位症有关的骨盆疼痛。在228名具有晚期前列腺癌的男性中的两个随机化的II期临床试验中,relugolix证实了将睾酮降低至非常低的水平和降低前列腺特异性抗原水平的能力,前列腺特异性抗原是关键的前列腺癌生物标志物。relugolix的这些结果与醋酸亮丙瑞林(通常用于雄激素剥夺治疗的GnRH激动剂)和四种地加瑞克(可注射的GnRH拮抗剂)的结果一致。与GnRH激动剂不同,当每天一次口服给药时,这些试验显示relugolix快速降低睾酮水平。Myovant Sciences计划针对relugolix开始三个多国III期阶段临床项目: 2017年第一季度,与子宫肌瘤相关的严重月经出血; 2017年上半年,妇女与子宫内膜异位症相关的疼痛; 2017年第一季度,男性患有晚期前列腺癌。Myovant Sciences预计将在2019年报告这些III期临床试验结果数据。此外,Myovant Sciences也在开发其第二个产品——RVT-602,一种寡肽kisspeptin类似物,作为辅助生殖的一部分,用于治疗女性不孕。Kisspeptin是刺激GnRH释放的天然存在的肽。RVT-602已经在约150名男性中进行了评估,但尚未在女性中进行研究。2017年下半年,我们预计将开始对妇女进行第一阶段健康志愿者研究,随后进行RVT-602的第二阶段概念验证试验。Myovant Sciences相信RVT-602有可能是一种更安全的替代人类绒毛膜促性腺激素,作为辅助生殖的一部分用于治疗女性不育症,基于发表的数据评估在接受辅助生殖的妇女的本机kisspeptin。Myovant Sciences Ltd.与Flo Health合作开发了一种数字工具,用于筛查月经量大的出血情况。

交易日期 交易人 职位 类型 交易份额 价格
2017-05-30 Seely (Lynn) Chief Executive Officer Buy 564111 --
2017-04-16 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 4432 --
2017-03-14 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 13091 --
2017-02-14 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 6845 --
2017-01-16 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 5727 --
2016-12-14 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 22141 --
2016-10-31 Takeda Pharmaceuticals Internati Beneficial Owner of More than 10% Class Buy 1977269 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Apo Asset Management GmbH 163198 0.18% 80114 96.43% 2019-07-31
Lord, Abbett & Co LLC 1965705 2.19% 52157 2.73% 2019-03-31
Janus Capital Management LLC 1970753 2.20% 631443 47.15% 2019-07-31
Eventide Asset Management, LLC 2469021 2.75% 264313 11.99% 2019-03-31
HHG PLC 2506392 2.80% -57674 -2.25% 2019-03-31
NovaQuest Capital Management, L.L.C. 3474645 3.88% -- -- 2019-03-31
RA Capital Management, LLC 3544227 3.95% -167322 -4.51% 2019-03-31
BB Biotech AG 3597882 4.01% -- -- 2019-03-31
Bellevue Asset Management AG 3910109 4.36% 312227 8.68% 2019-07-31
Victory Capital Management Inc. 1454323 1.62% 930750 177.77% 2019-07-31
Janus Capital International Ltd 941835 1.05% 396457 72.69% 2019-07-31
T. Rowe Price Associates, Inc. 812148 0.91% 1300 0.16% 2019-03-31
BAMCO Inc 168000 0.19% 28000 20.00% 2019-03-31
Monashee Investment Management LLC 180417 0.20% 180417 -- 2019-03-31
Advanced Series Trust 181070 0.20% 115260 175.14% 2019-07-31
BNY Mellon Investment Adviser, Inc. 253928 0.28% -- -- 2019-07-31
Rock Springs Capital Management LP 347500 0.39% -- -- 2019-03-31
Hartford Funds Management Company, LLC 351500 0.39% -- -- 2019-07-31
Adage Capital Partners Gp LLC 425000 0.47% -300000 -41.38% 2019-03-31
Cormorant Asset Management, LLC 650000 0.73% 650000 -- 2019-03-31
Millennium Management LLC 144761 0.16% 99487 219.74% 2019-03-31
Junked Platinum Investment Management Ltd 146552 0.16% -- -- 2019-03-31
Bank of New York Mellon Corp 369320 0.51% 357454 3012.42% 2018-12-31
Boston Co Asset Management LLC 271907 0.38% 271907 -- 2018-12-31
Emory University 111925 0.16% -12226 -9.85% 2019-03-31
Dreyfus Corporation 254018 0.35% 67 0.03% 2019-05-31
Jackson National Asset Management LLC 101746 0.14% 89880 757.46% 2019-04-30
FMG LLC 92695 0.13% -- -- 2019-04-30
JPMorgan Chase & Co 91595 0.13% -32068 -25.93% 2018-09-30
J.P. Morgan Securities Inc 91595 0.13% -32068 -25.93% 2018-09-30
Pacific Life Fund Advisors LLC (PLFA) 80476 0.11% -13687 -14.54% 2019-01-31
AMG Funds LLC 76809 0.11% 20880 37.33% 2018-12-31
BlackRock Inc 547600 0.80% -444378 -44.80% 2018-06-30
BlackRock (Luxembourg) SA 139249 0.20% -36923 -20.96% 2018-11-30
Tekla Capital Management LLC 150471 0.22% -249529 -62.38% 2018-11-30
BlackRock Advisors LLC 296306 0.43% -73244 -19.82% 2018-11-30
D. E. Shaw & Co LP 350000 0.51% -- -- 2018-03-31
Platinum Investment Management Ltd 54200 -- -- -- 2018-06-30
Takeda Pharmaceutical Co Ltd 7420625 -- 7420625 -- 2018-03-19
Viking Global Investors LP 37231342 -- -- -- 2017-12-31
SVF GP (Jersey) Ltd. 38341357 -- 1110015 2.98% 2018-04-02
Medical Strategy GmbH 43786 -- -- -- 2018-05-31
State Street Corp 46978 -- 3400 7.80% 2018-03-31
NORGES BANK 600000 -- -21719 -3.49% 2017-12-31
Sio Capital Management, LLC 73054 -- 73054 -- 2017-12-31
Ardsley Advisory Partners 100000 -- 100000 -- 2017-12-31
Qvt Financial LP 37231342 -- -- -- 2017-12-31
Great Point Partners LLC 160530 -- 160530 -- 2017-12-31
Takeda Pharmaceuticals International AG 7390530 -- 7390530 -- 2016-12-31
Dexxon Holdings Inc. 37231342 -- 37231342 -- 2016-12-31
Point72 Asset Management, L.P. 81100 -- 81100 -- 2017-09-30
Deerfield Management Co 400685 -- -- -- 2017-09-30
ING Investment Management LLC 421397 -- 21478 5.37% 2017-06-30
Deutsche Asset & Wealth Management Investment GmbH 2580 -- -93 -3.48% 2017-02-08
BlackRock Investment Management, LLC 299549 0.50% 299549 -- 2016-10-31
BlackRock Fund Advisors 300372 0.47% -3308 -1.09% 2017-02-07
Voya Investments, LLC 218225 0.36% 218225 -- 2016-12-31
Alps Advisors Inc 53651 0.09% -2588 -4.60% 2017-01-31
Voya Investment Management Co. LLC (US) 38820 0.06% 38820 -- 2016-12-31
Teachers Advisors Inc 30656 0.05% 30656 -- 2016-12-31
Vanguard Group Inc 28518 0.05% 28518 -- 2016-12-31
Northern Trust Asset Management 20718 0.03% 20718 -- 2016-12-31
Variable Annuity Life Insurance Co 19347 0.03% -- -- 2016-12-31
Charles Schwab Investment Management Inc 16900 0.03% 16900 -- 2016-12-31
Penn Mutual Asset Management Inc 10904 0.02% 10904 -- 2016-12-31
Northern Trust Investments Inc 6314 0.01% 6314 -- 2016-12-31
BlackRock 2968 -- 2968 -- 2016-12-31
John Hancock Investment Mgt Svcs, LLC 2855 -- 2855 -- 2016-12-31
Mellon Capital Management Corporation 2612 -- 2612 -- 2016-12-31
Goldman Sachs Asset Management LP 435184 0.72% 435184 -- 2016-12-31
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Hartford Healthcare Fund 299400 0.33% -- -- 2019-06-30
Eventide Gilead Fund 1470218 1.64% 264313 21.92% 2019-03-31
Victory RS Small Cap Growth Fund 1199460 1.34% 796120 197.38% 2019-06-30
Eventide Healthcare & Life Sciences Fund 998803 1.11% -- -- 2019-03-31
Janus Henderson Global Life Sciences Fd 918340 1.02% 396457 75.97% 2019-06-30
T. Rowe Price Health Sciences Fund 875076 0.98% 219572 33.50% 2019-06-30
Lord Abbett Developing Growth Fund 662893 0.74% 3693 0.56% 2019-05-31
Janus Henderson Venture Fund 451941 0.50% -- -- 2019-06-30
AMOne Medical Science Fund 87213 0.10% 31323 56.04% 2019-02-15
BNY Mellon Sm/Md Cp Gr Fd 252349 0.28% -- -- 2019-06-30
Lord Abbett Growth Opportunities Fund 207780 0.23% -- -- 2019-05-31
JNL Multi-Manager Small Cap Growth Fund 89880 0.10% 89880 -- 2019-03-31
Vanguard Health Care Index Fund 101642 0.11% 46146 83.15% 2019-06-30
APO Medical Opportunities 132542 0.15% 64714 95.41% 2019-06-30
Lord Abbett Micro Cap Growth Fund 146330 0.16% -- -- 2019-05-31
Victory RS Science and Technology Fund 156160 0.17% 70650 82.62% 2019-06-30
Baron Discovery Fund 168000 0.19% -- -- 2019-06-30
AST Small Cap Growth Opportunities Port 181070 0.20% 115260 175.14% 2019-06-30
JHancock Seaport Long/Short Fund 77700 0.09% 77700 -- 2019-05-31
1290 VT Micro Cap Portfolio 79906 0.09% 1026 1.30% 2019-05-31
USAA Science & Technology Fund 76200 0.09% 76200 -- 2019-05-31
Pacific Select Developing Growth Port 71014 0.08% -1078 -1.50% 2019-04-30
Lord Abbett Convertible Fund 93000 0.10% -- -- 2019-04-30
MEDICAL BioHealth 67786 0.09% -- -- 2019-02-28
Dreyfus/The Boston Co Sm/Md Cp Gr Fd 252349 0.35% -- -- 2019-03-31
VALIC Company I Health Sciences Fund 41476 0.06% -- -- 2019-02-28
AMG Managers Emerging Opportunities Fund 54296 0.08% -30 -0.06% 2019-01-31
TD Health Sciences Fund 38970 0.06% 1768 4.75% 2018-12-31
ON Janus Henderson Venture Portfolio 32501 0.05% -- -- 2018-12-31
FCP MEDICAL BioHealth-Trends 67786 0.10% -- -- 2018-10-31
Janus Henderson US Venture Fund 31885 0.05% -- -- 2018-09-30
BNY Mellon Small Cap Multi-Strategy Fund 30750 0.04% -- -- 2018-11-30
BGF World Healthscience Fund 139249 0.20% -36923 -20.96% 2018-06-30
Tekla Healthcare Investors 105329 0.15% -174671 -62.38% 2018-03-31
Tekla Life Sciences Investors 45142 0.07% -74858 -62.38% 2018-03-31
BlackRock Health Sciences Opps Port 296306 0.43% -73244 -19.82% 2018-06-30
FCP MEDICAL BioHealth 43786 0.06% -- -- 2018-06-30
ZIL Blackrock Global Fds Wld Health Sci 139249 0.20% -36923 -20.96% 2018-06-30
AXA/Lord Abbett Micro Cap K 82573 0.12% 16508 24.99% 2018-07-31
Fidelity 5229 0.01% -- -- 2018-09-12
Great-West Multi-Manager Sm Cp Gr Instl 9295 0.01% 6526 235.68% 2018-06-30
Thrivent Partner Ser Healthcare A 9579 0.01% -2422 -20.18% 2018-06-30
JNL/Mellon Capital Healthcare Sector B 11866 0.02% -- -- 2018-06-30
JHFunds2 Health Sciences NAV 15923 0.02% 2315 17.01% 2018-07-31
Eventide Healthcare & Life Sciences A 814762 1.26% 260941 47.12% 2018-06-30
Eventide Gilead N 786899 1.21% 767167 3887.93% 2018-06-30
Lord Abbett Developing Growth A 661878 0.97% 238063 56.17% 2018-07-31
Janus Global Life Sciences D 504363 0.78% 504363 -- 2018-06-30
Lord Abbett Growth Opportunities A 185243 0.27% 185243 -- 2018-07-31
Lord Abbett Micro Cap Growth I 161050 0.24% 33012 25.78% 2018-07-31
Pacific Select Small-Cap Growth I 70358 0.10% 24819 54.50% 2018-07-31
Baron Discovery Institutional 58200 0.09% 58200 -- 2018-06-30
VALIC Company I Health Sciences 42576 0.06% 7013 19.72% 2018-07-31
AMG Managers Emerging Opps Svc 33822 0.05% 33822 -- 2018-04-30
Lord Abbett Series Growth Opps VC 28676 0.04% 28676 -- 2018-07-31
Lord Abbett Series Developing Growth VC 19980 0.03% 8085 67.97% 2018-07-31
AMG Managers Special Equity Service 19430 0.03% 7248 59.50% 2018-07-31
JHVIT Health Sciences I 16459 0.02% 2703 19.65% 2018-07-31
PF Small-Cap Growth P 3039 -- 1086 55.61% 2018-07-31
BlackRock Health Sciences Opps Inv A 296306 0.46% -73244 -19.82% 2018-06-30
Pacific Select Health Sciences I 18789 0.03% -4570 -19.56% 2018-06-30
BlackRock Health Sciences 29453 0.05% 1500 5.37% 2017-03-31
Nuveen Small Cap Index I 527 -- -80 -13.18% 2017-03-31
Meeder Spectrum 80 -- -- -- 2018-04-30
AXA/Pacific Global Small Cap Value K 154 -- -- -- 2017-04-30
Schwab Instl Small Cap Tr Fd-Instl 20154 0.03% 20154 -- 2016-12-31
Voya SmallCap Opportunities Port I 35442 0.06% 35442 -- 2016-12-31
Voya Small Cap Growth Trust 38820 0.06% 38820 -- 2016-12-31
ALPS Medical Breakthroughs ETF 53651 0.09% -2588 -4.60% 2017-01-31
Voya Small Company I 52019 0.09% 52019 -- 2016-12-31
Voya Small Company Port I 57872 0.10% 57872 -- 2016-12-31
iShares Russell 2000 Growth 69224 0.11% -- -- 2017-02-07
Voya SmallCap Opportunities A 72892 0.12% 72892 -- 2016-12-31
CREF Stock R1 19116 0.03% 19116 -- 2016-12-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 20718 0.03% 20718 -- 2016-12-31
VALIC Company I Small-Mid Growth 19347 0.03% -- -- 2016-12-31
Schwab Small Cap Index 16900 0.03% 16900 -- 2016-12-31
iShares Russell 2000 Value 19120 0.03% -78 -0.41% 2017-02-07
The Vanguard Russell 2000 Growth Index 13500 0.02% 13500 -- 2016-12-31
TIAA-CREF Small-Cap Blend Idx Inst 11540 0.02% 11540 -- 2016-12-31
Penn Series SMID Cap Growth 10104 0.02% 10104 -- 2016-12-31
Vanguard Russell 2000 ETF 8110 0.01% 8110 -- 2016-12-31
Northern Small Cap Index 6314 0.01% 6314 -- 2016-12-31
Goldman Sachs Small/Mid Cap Growth A 435184 0.72% 435184 -- 2016-12-31

Frank L. Karbe Frank L. Karbe occupies the position of Chief Financial & Accounting Officer of Myovant Sciences Ltd. and Chief Financial & Accounting Officer of Myovant Sciences, Inc. He is also on the board of Aduro BioTech, Inc. In the past he was President for The Color Run LLC, Chief Financial Officer & Executive Vice President for Exelixis, Inc. and Vice President-Healthcare Group at Goldman Sachs & Co. LLC. Frank L. Karbe received an MBA from WHU-Otto Beisheim School of Management.
Wayne S. DeVeydt Mr. Wayne S. DeVeydt is Executive Vice President & Chief Financial Officer at Anthem, Inc., Chief Financial Officer at Anthem Blue Cross Life & Health Insurance Co., Chief Financial Officer at UniCare Health Plans of Texas, Inc., Chief Financial Officer & Executive Vice President at Anthem Life & Disability Insurance Co. and President at Anthem Insurance Cos., Inc. He is on the Board of Directors at Myovant Sciences Ltd., NiSource, Inc., Boys & Girls Clubs of America, BCS Financial Corp., Chamber of Commerce of The United States of America, Resolution Health, Inc. and Wellness Community. Mr. DeVeydt was previously employed as Chief Financial Officer & Executive Vice President by Anthem, Inc. and Lead Engagement Partner by PricewaterhouseCoopers LLP. He also served on the board at The Children's Museum of Indianapolis, Inc. and Y.M.C.A. Foundation of Greater Indianapolis. He received his undergraduate degree from the University of Missouri.
Lynn Seely Presently, Lynn Seely holds the position of President, Chief Executive Officer & Director at Myovant Sciences Ltd. and President & Chief Executive Officer for Myovant Sciences, Inc. (a subsidiary of Myovant Sciences Ltd.). She is also on the board of Blueprint Medicines Corp. In her past career Lynn Seely occupied the position of Vice President-Clinical Development at Anesiva, Inc. and Vice President-Clinical Development at Corgentech, Inc. (a subsidiary of Anesiva, Inc.), Chief Medical Officer at Orion Acquisition Corp. II, Vice President-Clinical Development at Pro-Duct Health, Inc., Vice President-Clinical Development at Cytyc Health Corp., Chief Medical Officer of Medivation, Inc., Chief Resident at Yale-New Haven Hospital, Inc., Associate Director-Clinical Development at Chiron Corp. and Faculty Member at the University of California San Diego. She received an undergraduate degree from the University of Oklahoma and a doctorate from the University of Oklahoma College of Medicine.
Mark J. Guinan Currently, Mark J. Guinan occupies the position of Chief Financial Officer & Executive Vice President at Quest Diagnostics, Inc. Mr. Guinan is also on the board of Roivant Sciences GmbH, Myovant Sciences Ltd. and Q Squared Solutions Holdings Ltd. In his past career Mr. Guinan was Vice President-Finance for Global Pharmaceutical Group, Chief Financial Officer & Senior Vice President for Hill-Rom Holdings, Inc., Principal at Procter & Gamble Co. and Chief Procurement Officer at Johnson & Johnson. He received an undergraduate degree from the University of Notre Dame and an MBA from Olin Business School.
Myrtle S. Potter Myrtle S. Potter is an entrepreneur and businessperson who founded Myrtle Potter & Co. LLC, Myrtle Potter Media, Inc. and Astra Merck, Inc. and who has been the head of 6 different companies. Presently, she is Chairman for Myovant Sciences Ltd. and Chairman at Urovant Sciences Ltd. Ms. Potter is also Chairman-Vant Operation at Roivant Sciences, Inc. and on the board of 11 other companies. In the past Ms. Potter was Chief Executive Officer of Myrtle Potter & Co. LLC, Chief Executive Officer at Chapman Properties, Inc., Chief Executive Officer of Myrtle Potter Media, Inc., Vice President at Merck & Co., Inc., President-US Cardiovascular & Metabolics at Bristol-Myers Squibb Co. and President & Chief Operating Officer for Genentech, Inc. She received an undergraduate degree from The University of Chicago.
Keith S. Manchester Dr. Keith S. Manchester, MD, is Managing Director & Head of Life Sciences at QVT Financial LP where he has been employed since 2005, and focuses on investments in both publicly traded and privately owned life sciences companies. He is also a director of Arbutus Biopharma. Prior to joining QVT Financial, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, he was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, he was an investment banker in the healthcare group at Goldman, Sachs & Co. He was a director of OnCore Biopharma from November 2014 to March 2015. He received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.
Frank M. Torti Frank M. Torti is a businessperson who has been at the head of 5 different companies and currently is Chairman of Immunovant, Inc., Chairman of Dermavant Sciences Ltd., Chairman of Arbutus Biopharma Corp., Partner at NEA Management Co. LLC, Chairman for Axovant Gene Therapies Ltd. and Chairman at Dermavant Sciences, Inc. Dr. Torti is also Chairman-Vant Investment at Roivant Sciences, Inc. and on the board of 6 other companies. In the past Frank M. Torti was Principal at Wasatch Advisors, Inc. and Principal at Revolution Health Group LLC. He received a doctorate from UNC School of Medicine, an MBA from Harvard Business School and an undergraduate degree from the University of North Carolina at Chapel Hill.
Vivek Ramaswamy Founder of Roivant Sciences GmbH and Campus Venture Network, Inc., Vivek Ramaswamy is a businessperson who has been at the head of 8 different companies and presently holds the position of President & Chief Executive Officer for Roivant Sciences GmbH and President & Chief Executive Officer for Roivant Sciences, Inc. (a subsidiary of Roivant Sciences GmbH). Vivek Ramaswamy is also on the board of Roivant Sciences Ltd. and Myovant Sciences Ltd. (former Chairman). In his past career he held the position of Chairman at Arbutus Biopharma Corp. and Chairman for Arbutus Biopharma, Inc. (a subsidiary of Arbutus Biopharma Corp.), President for Campus Venture Network, Inc., Investment Analyst at QVT Financial LP, Director at Axovant Gene Therapies Ltd. and Chief Executive Officer of Axovant Sciences, Inc. He received a graduate degree from Yale Law School and an undergraduate degree from Harvard College.
Frank L. Karbe Frank L. Karbe is Chief Financial & Accounting Officer at Myovant Sciences Ltd. and Chief Financial & Accounting Officer for Myovant Sciences, Inc. He previously occupied the position of President for The Color Run LLC, Chief Financial Officer & Executive Vice President of Exelixis, Inc. and Vice President-Healthcare Group at Goldman Sachs & Co. LLC. Mr. Karbe received an MBA from WHU-Otto Beisheim School of Management.
Teresa Perney Currently, Teresa Perney occupies the position of SVP-Regulatory Affairs & Quality Assurance at Myovant Sciences Ltd. She received an undergraduate degree from Northwestern University and a doctorate from The University of Chicago.
Jeffrey D. Nornhold Jeffrey D. Nornhold is on the board of Impax Laboratories (Taiwan), Inc. and Senior VP-Pharmaceutical Operations & Development at Myovant Sciences Ltd. He previously was Vice President-Quality Operations at Allergan Plc and Vice President-Quality Operations at Actavis, Inc. (a subsidiary of Allergan Plc) and Senior Vice President-Technical Operations at Impax Laboratories LLC. Jeffrey D. Nornhold received an undergraduate degree from Bowling Green State University and an MBA from USC Marshall School of Business.
Terrie Curran Ms. Terrie Curran is an Independent Director at Myovant Sciences Ltd. and a President-Global Inflammation & Immunology at Celgene Corp. She is on the Board of Directors at BioNJ, Inc., Myovant Sciences Ltd. and Roivant Sciences GmbH. Ms. Curran was previously employed as an Independent Director by H. Lundbeck A/S, a Senior Vice President by Merck & Co., Inc., and a General Manager by Schering-Plough Corp. She received her undergraduate degree from the University of Technology Sydney.
Kathleen Sebelius Kathleen Sebelius is the former Governor of State of Kansas (Kansas). Ms. Sebelius is Chief Executive Officer at this company. Ms. Sebelius is also Co-Chairman at The Aspen Institute, Inc. and Member of The Democratic Party (United States) and on the board of 8 other companies. In the past Kathleen Sebelius occupied the position of Senior Advisor at Just Inc, Governor at State of Kansas (Kansas) and Secretary at US Department of Health & Human Services (DC). She received an undergraduate degree from Trinity College (District of Columbia) and a graduate degree from the University of Kansas.
Marianne L. Romeo Marianne L. Romeo is on the board of Bermuda Society For Healthcare Risk Management and Head-Global Transactions & Risk Management at Myovant Sciences Ltd. In the past Ms. Romeo occupied the position of Head-Global Transactions & Risk Management at Roivant Sciences GmbH, Managing Director at Bowring Marsh (Bermuda) Ltd. and Director & Head-Global Transactions at Axovant Sciences Ltd. Ms. Romeo received an undergraduate degree from Tufts University and a graduate degree from Hunter College.
Matthew Lang Matthew Lang holds the position of Secretary & General Counsel of Myovant Sciences Ltd. and Secretary & General Counsel at Myovant Sciences, Inc. In the past Mr. Lang occupied the position of Vice President for Gilead Sciences, Inc. Mr. Lang received an undergraduate degree from Queen's University and a graduate degree from The University of Pennsylvania Law School.
Juan Camilo Arjona Ferreira Currently, Juan Camilo Arjona Ferreira occupies the position of Chief Medical Officer of Myovant Sciences Ltd. He previously was Executive Director-Clinical Research at Merck & Co., Inc. and Senior Vice President-Clinical Development at Shionogi, Inc. He received a graduate degree from Universidad del Rosario.
Teresa Perney Currently, Teresa Perney occupies the position of SVP-Regulatory Affairs & Quality Assurance at Myovant Sciences Ltd. She received an undergraduate degree from Northwestern University and a doctorate from The University of Chicago.
Julie Tran Presently, Julie Tran is Vice President-Human Resources of Myovant Sciences Ltd. Ms. Tran received a graduate degree and an MBA from Golden Gate University and an undergraduate degree from San Jose State University.
Kim Sablich Kim Sablich is Chief Commercial Officer at Myovant Sciences Ltd. Ms. Sablich received an undergraduate degree from Denison University and an MBA from The Wharton School of the University of Pennsylvania.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐